QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

QIAGEN N.V.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026

$46.55+0.42 (+0.91%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 24.0
Dividend yield: 0.54%

QIAGEN N.V. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	2,090	1,978	1,965	2,142	2,252	1,870	1,526	1,502	1,418	1,338	1,281	1,345	1,302	1,254	1,170	1,087	1,010	893
Cost of Revenue	791	1,011	732	757	801	638	521	501	495	493	454	480	486	430	420	372	343	293
Gross Profit	1,299	967	1,234	1,385	1,451	1,233	1,005	1,001	923	845	827	865	815	824	750	716	667	600
Research & Development	188	193	199	190	190	149	157	162	154	150	147	164	146	122	131	126	108	97
Selling, General & Admin	584	564	579	604	584	525	504	497	478	–	–	–	–	–	–	–	–	–
Selling & Marketing	458	451	460	474	456	414	392	392	376	376	360	376	372	344	307	267	245	227
General & Administrative	126	113	119	130	128	112	112	105	102	–	–	–	–	–	–	–	–	–
Advertising Expenses	8.70	9.60	12	16	14	9.50	8.10	8.10	7.20	8.40	7.20	7.00	7.60	6.60	6.30	7.60	11	22
Operating Expenses	834	870	824	853	821	846	1,031	734	769	746	647	704	752	654	650	527	487	454
Operating Income	466	98	410	531	630	386	-26	267	153	99	179	162	63	170	100	189	180	146
Interest Expense	33	44	53	58	54	71	74	67	50	39	37	39	31	23	25	28	30	38
Interest & Investment Income	64	68	79	33	9.56	10	22	21	11	6.78	4.75	3.96	2.30	2.38	6.13	4.46	3.52	9.51
Income from Equity Investments	4.40	5.72	4.16	3.76	12	5.02	2.08	2.59	3.16	2.82	0.66	3.48	1.75	1.85	–	–	–	–
Other Non-Operating Income	24	23	20	-19	-4.25	53	-52	-41	-39	-42	-43	-42	-26	-25	-3.38	-15	-7.88	-26
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	79	–	–	–	41	75	–	–	–
Asset Impairment Charges	22	203	4.16	13	0	1.43	145	17	0	0	0	20	16	12	1.80	–	–	–
Gain (Loss) on Investments	-0.97	-0.43	0	-6.23	36	122	0	0	–	–	–	–	–	–	0	0	12	–
Pretax Income	490	121	430	513	626	439	-78	226	114	57	136	119	37	145	96	173	172	–
Income Tax Expense	65	38	89	89	113	80	-36	35	74	-23	6.40	2.46	-32	16	1.26	29	35	30
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	-41	190	40	80	130	117	69	130	95	144	138	90
Minority Interest in Earnings	–	–	–	–	–	–	–	0	0	-0.10	-0.25	0.57	0.03	0.03	-1.09	0	0	0.49
Net Income	425	84	341	423	513	359	-41	190	40	80	130	116	69	130	96	144	138	89
EPS (Basic)(per share)	1.96	0.38	1.50	1.86	2.25	1.57	-0.18	0.84	0.18	0.34	0.56	0.50	0.30	0.55	0.41	0.62	0.67	0.45
EPS (Diluted)(per share)	1.94	0.37	1.48	1.84	2.21	1.53	-0.18	0.82	0.17	0.34	0.55	0.48	0.29	0.54	0.40	0.60	0.64	0.44
Shares Outstanding (Basic, Weighted)(shares)	217	223	228	228	228	228	227	227	228	235	233	233	234	236	234	233	207	197
Shares Outstanding (Diluted, Weighted)(shares)	219	225	231	230	232	234	227	233	233	239	239	243	242	241	239	240	214	204
Dividend per Share(per share)	0.25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EBITDA	660	301	615	740	845	591	205	473	370	312	371	362	263	368	267	331	229	188
Provision for Credit Losses	0	-0.01	0.01	5.57	2.16	1.33	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 62.2%
Operating margin: 22.3%
Net margin: 20.3%
Return on equity, FY2025: 11.6%

Financial strength

Current ratio: 3.90
Debt to equity: 0.44
Debt to assets: 26.3%
Cash to current liabilities: 163.8%

Valuation

P/E ratio: 24.0
Price to sales: –
Price to book: –
Dividend yield: 0.54%